Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00701402 |
The purpose of this observational study is to describe the time to lipid-lowering drug implementation in the management of dyslipidemic patients, according to the cardiovascular risk level.
Condition |
---|
Dyslipidemia |
Study Type: | Observational |
Study Design: | Cohort, Cross-Sectional |
Official Title: | Survey on Time to Lipid-Lowering Drug Implementation on Dyslipidemic Patients in General Practice. |
Estimated Enrollment: | 4500 |
Study Start Date: | June 2008 |
Study Completion Date: | February 2009 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
First three consecutive dyslipidemic patients seen by GP
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Alain Castaigne | AstraZeneca |
Responsible Party: | AstraZeneca Pharmaceuticals ( Alain Castaigne, Medical Director ) |
Study ID Numbers: | NIS-CFR-DUM-2007/9 |
Study First Received: | June 18, 2008 |
Last Updated: | April 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00701402 History of Changes |
Health Authority: | France: French Data Protection Authority |
time to lipid-lowering drug implementation dyslipidemic patients |
Antimetabolites Metabolic Diseases Antilipemic Agents |
Metabolic Disorder Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Metabolic Diseases Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Antilipemic Agents Pharmacologic Actions Dyslipidemias Lipid Metabolism Disorders |